Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — WA Life Sciences Broker Meets Biotech 2025
24 slides from Proteomics International Laboratories's conference presentation, Mar 20, 2025
Slide 1: ASX Release: Proteomics International to present at Broker Meets Biotech
ASX Release 20 March 2025 ASX code: PIQ Investor Presentation Proteomics International to present at Broker Meets Biotech Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscomb
Slide 2: Broker Meets Biotech Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Broker Meets Biotech Investor Presentation - suite of diagnostic tests primed for launch Perth, 20th March 2025 Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of precision diagnostics Launching four first-in-class tests driven by a proprietary platform technology: • A novel and accurate blood test for predicting the onset of chronic kidney disease in type 2 an
Slide 5: Corporate Overview
Corporate Overview ASX: PIQ Financial and Corporate Corporate Snapshot ASX code PIQ • Top 40 Shareholders hold 41% Market Capitalisation A$65.5m ➢ Directors are highly aligned with shareholders holding 13% Cash (31 Dec 2024) A$5.3m Share Price (18 Mar 2025) A$0.50 • Revenue generating Shares on issu
Slide 6: Board of Directors
Board of Directors ASX: PIQ Dr James Williams PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Chair Accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Involved from startup to commercialisation, i
Slide 7: Commercialisation Team
Commercialisation Team ASX: PIQ Phillip Prather Jacqueline Gray Chief Commercial Officer Chief Financial Officer & Head of Corporate Development Phillip brings extensive leadership in the global medical devices Jacqueline has held senior leadership roles with global media and industry, particularly
Slide 8: Go-to-Market optionality: Synergistic pathways
Go-to-Market optionality: Synergistic pathways ASX: PIQ Initial sales led by Direct to Consumer with option to expand through licencing Direct to consumer (DTC) and digital marketing pathway PI Reference Blood collection engaged and PI receives payment Laboratories samples run Telehealth consult: Pr
Slide 9: Go-to-Market
Go-to-Market ASX: PIQ Direct to Consumer (DTC) digital solution implemented • Launched in Australia in Q1 CY25 ➢ Automated immunoassay established ➢ Clinical ISO 15189 certification pending ➢ Blood collection logistics established ➢ GP practices engaged ➢ Integrated digital solution enacted 8
Slide 10: Patient journey & Revenue capture model
Patient journey & Revenue capture model ASX: PIQ Managed via a fully integrated digital solution @ www.myTEST.health @ Consumer Browsing diabetes/ Keyword SEM Patient Patient kidney health Online advert Payment Gateway GP provides test results to patient campaign White Label Test Website & guides cl
Slide 11: GP blast followed by relationship nurture workflows
GP blast followed by relationship nurture workflows ASX: PIQ Comprehensive Customer Relationship Management (CRM) system established A blood test which can identify the onset of chronic kidney disease up to four years before clinical symptoms appear GP Requests eDetail ProD GP Requests eDetail ProEs
Slide 12: GP outreach program
GP outreach program ASX: PIQ Multiple contact points established for physician engagement GP Clinic Marketing blast Marketing blast Outreach (WA/NT clinics) (Rest of AU clinics*) Clinic scheduling GP clinics detailed GP clinics detailed and communication system; 3000 of 6500 (WA/NT clinics) (Rest of
Slide 13: Market launch: Australia and USA
Market launch: Australia and USA ASX: PIQ Australia USA ISO 17025 established PI Reference Laboratory CLIA certification established ISO 15189 pending PromarkerD: 84,000 pa PromarkerD: 84,000 pa Initial capacity of laboratory PromarkerEso: 32,000 pa PromarkerEso: 32,000 pa PromarkerD: Q1 CY25 Promar
Slide 14: Market launch: strategic rationale
Market launch: strategic rationale ASX: PIQ The Direct to Consumer route provides maximum optionality: ➢ Fastest and most cost-effective path to market ➢ Scalable with low cost of customer acquisition compared to traditional sales model ➢ Provides a platform to: ▪ partner with virtual care providers
Slide 15: Multiple Value Drivers in H1 CY25
Multiple Value Drivers in H1 CY25 ASX: PIQ Milestone TARGET Qtr Dec Mar Jun Impact Commercial US reference lab established ✓ Key to first US sales and reimbursement First Sales PromarkerD in USA Initiate pathway to significant revenues Australian clinical lab certification established PromarkerD lau
Slide 16: Summary – Exceptional Growth Opportunity
ASX: PIQ • Disruptive, cutting-edge technology & proven in-house Summary – diagnostics platform • Multiple patented tests Exceptional • PromarkerD test de-risked, patented, commercial launch Growth ready Opportunity • PromarkerEso, PromarkerEndo and OxiDx tests nearing market entry • Tests are scala
Slide 17: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ 16
Slide 18: Supplemental – the Promarker suite of diagnostic tests
Supplemental – the Promarker® suite of diagnostic tests 17
Slide 19: The Need: Target Populations for DKD, Endo and Eso
The Need: Target Populations for DKD, Endo and Eso ASX: PIQ 10.5% of the global adult 1 in 9 women have 1-2% of western populations at risk population have diabetes endometriosis of esophageal cancer (currently screened by ultrasound or MRI and (Gastroesophageal reflux disease (GERD) currently diagn
Slide 20: PromarkerD: Diabetic Kidney Disease
PromarkerD: Diabetic Kidney Disease ASX: PIQ Intellectual Property Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers 72% of the world’s diabetes patients CE Mark (EU) registration received for the PromarkerD Immunoassay IVD Regulatory US sales utilising Lab Dev
Slide 21: PromarkerEso: Esophageal Cancer
PromarkerEso: Esophageal Cancer ASX: PIQ First-in-class blood test ‘PromarkerEso’ ready for commercialisation Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) esophageal adenocarcinoma (EAC) patients ➢ Only 50% of EAC patients report chronic acid reflux ➢ 9
Slide 22: PromarkerEndo: Endometriosis
PromarkerEndo: Endometriosis ASX: PIQ First-in-class blood test ‘PromarkerEndo’ nearing commercialisation Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) symptomatic patients (pelvic pain but surgically-diagnosed absence of endometriosis) 3) endometriosis
Slide 23: OxiDx: Oxidative Stress
OxiDx: Oxidative Stress ASX: PIQ Groundbreaking blood test nearing commercialisation What is Oxidative Stress? Targeting commercial use of OxiDx technology: • Oxidative stress occurs when the body’s ➢ Athletic monitoring tool for competition preparedness: antioxidant defences are overwhelmed by an o
Slide 24: Proteomics International (Est'd 2001)
Proteomics International (Est’d 2001) ASX: PIQ ASX:PIQ Identity Proteomics International is a medical technology company specialising in predictive diagnostics and advanced analytical services using proteomics – the industrial scale study of the structure and function of proteins. Mission To improve
Proteomics International Laboratories — WA Life Sciences Broker Meets Biotech 2025 on 6ix